KDR and osteosarcoma: Although anlotinib can significantly inhibit the growth of osteosarcoma cells and xenografts by suppressing VEGFR2 and MET phosphorylation, the prognosis of advanced osteosarcoma patients treated with anlotinib remains controversial [12].